Dr Ilaria Pagani
School of Medicine
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
I am a biomedical researcher in the field of cancer. I previously studied breast cancer and proliferative vitreoretinopathy, but my current and future focus are haematological diseases, in particular chronic myeloid leukaemia (CML). I have a PhD in Experimental Medicine and Oncology, completed in 2012, and I am a Specialist in Medical Genetics, completed in November 2016 with highest honours. I am a new recipient of the prestigious Beat Cancer Project Mid-career Fellowship valued at $300,000, awarded by the Cancer Council South Australia for the years 2020-2022. I also been awarded the SAHMRI seed funding grant for mid-career researchers valued at $30,000.The aim of my fellowship is identifying and exploiting metabolic dependencies for improved therapeutic outcomes in CML patients. Only ~20% of CML patients are able to achieve optimal outcomes, and 20-30% develop resistance to tyrosine kinase inhibitor therapy or develop fatal blast crisis. This is driven by the failure of current therapies to eradicate leukaemic stem/progenitor cells. My mid-term goal is to develop targeted therapies by re-purposing FDA-approved drugs targeting survival signals and metabolic dependencies in these leukaemic stem/progenitor cells. This approach will enable rapid translation into clinical practice, with an immediate impact on the lives of CML patients.As Principal Investigator in 2019 I have been awarded the first international-John-Goldman-Research-Award valued at $130,000 for 2 years, beating 29 applicants from 14 countries. The aim of this second project is understanding the causes of treatment free remission after discontinuation of therapy in CML, and identifying patients who can safely cease therapy by using artificial intelligence. This will lead to the development of new targeted therapies for patients predicted to relapse.I am an Ambassador for the European Association for Cancer Research, promoting the advancement of cancer research for public benefit. I have been recently appointed President of the Association for Research between Italy and Australia, which aim is to diffuse research and create network between researchers, costumers and governments. I am a passionate science communicator, engaging with media and with the community, and I am and advocate for women in STEM.
| Date | Position | Institution name |
|---|---|---|
| 2017 - 2020 | Affiliated Lecturer | University of Adelaide, Adelaide |
| 2015 - 2018 | Post-Doctoral Researcher | South Australian Health and Medical Research Institute, Adelaide |
| 2014 - 2014 | Visiting-Post Doc | South Australian Health and Medical Research Institute, Adelaide |
| 2012 - 2014 | Post-Doctoral Researcher | University of Rome Tor Vergata, Rome |
| 2012 - 2012 | Visiting Post-Doc | Medical Research Council (MRC), London |
| 2011 - 2012 | Post-Doctoral Researcher | University of Insubria, Varese |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2020 | Award | Mid-Career Researcher Presentation First Prize | SAHMRI | Australia | - |
| 2019 | Award | International John Goldman Research Award | European School of Haematology (ESH) | Australia | - |
| 2019 | Award | ESH Travel Grant covering all expenses | European School of Haematology | Australia | - |
| 2018 | Invitation | Technical expert/guide to the Italian Delegation in SAHMRI | South Australian Health and Medical Research Institute (SAHMRI) | Australia | - |
| 2018 | Invitation | Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. | South Australian Health and Medical Research Institute (SAHMRI) | Australia | - |
| 2018 | Award | Best poster Award | New Directions in Leukaemia Research (NDLR) 2018 Meeting | Australia | $250 |
| 2016 | Award | Competitive selective Beat Cancer Project Travel Grant 2016 | Cancer Council South Australia | Australia | $1250 |
| 2016 | Invitation | Invited to judge oral/poster presentations for the EMBL Australia Postgraduate Symposium 2016 at SAHMRI, Adelaide, Australia. | EMBL Australia | Australia | - |
| 2016 | Achievement | Invited speaker to the 2016 Leukaemia Foundation Patient Education Conference, CML Session, Adelaide University, Australia. | Leukaemia Foundation | Australia | - |
| 2016 | Achievement | Invited speaker to the Hematology Seminar, S.A. Pathology, Adelaide, SA, Australia | SA Pathology | Australia | - |
| 2016 | Achievement | Invited speaker to the Cancer in SA Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. | South Australian Health and Medical Research Institute (SAHMRI) | Australia | - |
| 2015 | Achievement | Invited speaker to the Blood Club Translational Research Meeting, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia. | South Australian Health and Medical Research Institute (SAHMRI) | Australia | - |
| 2014 | Award | Top 10 Best Abstracts | European Society Human Genetics (ESHG), Milan, Italy | Italy | - |
| 2013 | Award | American Society of Hematology (ASH) International Post-doctoral Fellow (IPDF) approval and $500 ASH Abstract Achievement Award | American Society of Hematology (ASH) | Italy | $500 |
| 2012 | Fellowship | competitive selective 3 years - Italian Association for Cancer Research" (AIRC) Fellowship | Italian Association for Cancer Research (AIRC) | Italy | - |
| 2011 | Award | Competitive Selective Travel Fellowship covering all expenses to participate at the 11th FEBS Young Scientist Forum and at 36th FEBS Congress. | FEBS | Italy | - |
| 2011 | Fellowship | Italian Association against Leukaemia and Lymphoma (AIL) Fellowship | Italian Association against Leukaemia and Lymphoma (AIL) | Italy | - |
| 2007 | Scholarship | Insubria University PhD Scholarship, Varese, Italy. | Insubria University | Italy | - |
| Language | Competency |
|---|---|
| English | Can read, write, speak, understand spoken and peer review |
| French | Can read, write, speak and understand spoken |
| Italian | Can read, write, speak, understand spoken and peer review |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2012 | University of Insubria, Varese | Italy | PhD |
| 2011 - 2016 | University of Milan, Milan | Italy | Specialist in Medical Genetics |
| 2007 | University of Insubria, Varese | Italy | Master Degree in Molecular Biology |
| Date | Title | Institution name | Country |
|---|---|---|---|
| 2008 | State Examination for the qualification in Biological Science | University of Insubria, Varese | Italy |
| Year | Citation |
|---|---|
| 2026 | Naderi, Z., Sadras, T., Branford, S., Shanmuganathan, N., & Pagani, I. S. (2026). Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 21(1), 13 pages. |
| 2025 | Tolland, M., Ross, D. M., White, D., Hughes, T. P., & Pagani, I. S. (2025). Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities. Cancers, 17(18), 21 pages. Scopus1 WoS1 Europe PMC1 |
| 2024 | Pellegrino, M., Occhiuzzi, M. A., Grande, F., Pagani, I. S., Aquaro, S., & Tucci, P. (2024). Modulation of energetic and lipid pathways by curcumin as a potential chemopreventive strategy in human prostate cancer cells. Biochemical and Biophysical Research Communications, 735, 10 pages. Scopus4 WoS3 Europe PMC3 |
| 2023 | Shanmuganathan, N., Wadham, C., Shahrin, N., Feng, J., Thomson, D., Wang, P., . . . Branford, S. (2023). Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 108(9), 2380-2395. Scopus25 WoS28 Europe PMC18 |
| 2023 | Pagani, I. S., Shanmuganathan, N., Dang, P., Saunders, V. A., Grose, R., Kok, C. H., . . . Ross, D. M. (2023). Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood, 142(25), 2192-2197. Scopus9 WoS9 Europe PMC8 |
| 2022 | Pagani, I. S., Poudel, G., & Wardill, H. R. (2022). A Gut Instinct on Leukaemia: A New Mechanistic Hypothesis for Microbiota-Immune Crosstalk in Disease Progression and Relapse. Microorganisms, 10(4), 713-1-713-14. Scopus13 WoS9 Europe PMC9 |
| 2022 | Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12. Scopus22 WoS23 Europe PMC18 |
| 2022 | Poudel, G., Tolland, M. G., Hughes, T. P., & Pagani, I. S. (2022). Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers, 14(14), 18 pages. Scopus65 WoS54 Europe PMC44 |
| 2022 | Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131. Scopus2 WoS2 Europe PMC1 |
| 2021 | Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207. Scopus80 WoS73 Europe PMC53 |
| 2020 | Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . . . Ross, D. M. (2020). Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 34(4), 1052-1061. Scopus44 WoS44 Europe PMC38 |
| 2020 | Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . . . Ross, D. M. (2020). Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia. Leukemia and Lymphoma, 61(10), 2527-2529. Scopus9 WoS6 Europe PMC4 |
| 2019 | Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . . Yong, A. S. M. (2019). Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology, 186(3), e56-e60. Scopus13 WoS12 Europe PMC13 |
| 2018 | Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., . . . Ross, D. M. (2018). BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica, 103(12), 2026-2032. Scopus37 WoS29 Europe PMC24 |
| 2018 | Ross, D., Pagani, I., Shanmuganathan, N., Kok, C., Seymour, J., Mills, A., . . . Hughes, T. (2018). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 32(12), 2572-2579. Scopus75 WoS69 Europe PMC59 |
| 2017 | Pagani, I. S., Kok, C. H., Saunders, V. A., Van der Hoek, M. B., Heatley, S. L., Schwarer, A. P., . . . Ross, D. M. (2017). A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemia. The Journal of molecular diagnostics : JMD, 19(5), 711-721. Scopus6 WoS5 Europe PMC7 |
| 2015 | Porta, G., Pagani, I. S., & Pirrone, C. (2015). gDNA Q-PCR for clinical monitoring of CML. Cell Cycle, 14(23), 3659-3660. Scopus6 WoS6 Europe PMC5 |
| 2014 | Pagani, I. S., Spinelli, O., Mattarucchi, E., Pirrone, C., Pigni, D., Amelotti, E., . . . Porta, G. (2014). Genomic quantitative real-time PCR proves residual disease posivitity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia. Oncoscience, 1(7), 510-521. Scopus31 Europe PMC24 |
| 2014 | Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2014). Erratum: OTX1 expression in breast cancer is regulated by p53 (Oncogene (2011) 30 (3096-3103) doi:10.1038/onc.2011.31). Oncogene, 33(10), 1340. |
| 2013 | Azzolini, C., Pagani, I. S., Pirrone, C., Borroni, D., Donati, S., Al Oum, M., . . . Porta, G. (2013). Expression of VEGF-A, otx homeobox and p53 family genes in proliferative vitreoretinopathy. Mediators of Inflammation, 2013, 8 pages. Scopus28 WoS26 Europe PMC25 |
| 2011 | Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2011). Erratum: OTX1 expression in breast cancer is regulated by p53 (Oncogene (2011) 30 (3096-3103) DOI: 10.1038/onc.2011.31). Oncogene, 30(27), 3104. |
| 2011 | Terrinoni, A., Pagani, I. S., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Porta, G. (2011). OTX1 expression in breast cancer is regulated by p53. Oncogene, 30(27), 3096-3103. Scopus37 WoS37 Europe PMC35 |
| 2011 | Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2011). Erratum: The mammary gland and the homeobox gene otx1. (Breast Journal (2010) 16:1 (S53-S56)). Breast Journal, 17(5), 568. |
| 2010 | Pagani, I. S., Terrinoni, A., Marenghi, L., Zucchi, I., Chiaravalli, A. M., Serra, V., . . . Porta, G. (2010). The mammary gland and the homeobox gene Otx1. Breast Journal, 16(SUPPL. 1), S53-S56. Scopus13 WoS12 Europe PMC12 |
| Year | Citation |
|---|---|
| 2023 | Pagani, I. S., & Torresi, T. (2023). Italian–Australian Scientific and Research Cooperation. In G. Abbondanza, & S. Battiston (Eds.), Italy and Australia Redefining Bilateral Relations for the Twenty-First Century (pp. 241-265). Springer Nature Singapore. DOI |
| Year | Citation |
|---|---|
| 2024 | Branford, S., Fernandes, A., Wadham, C., Maqsood, M., Shahrin, N. H., Ross, D. M., . . . Shanmuganathan, N. (2024). Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure. In BLOOD Vol. 144 (pp. 996-997). FL, Orlando: ELSEVIER. DOI WoS1 |
| 2024 | Shanmuganathan, N., Wadham, C., Yeung, D., Shahrin, N. H., Fernandes, A., Maqsood, M., . . . Branford, S. (2024). Strong Association between Cancer Gene Variants at Diagnosis, Especially<i> ASXL1,</i> and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors. In BLOOD Vol. 144 (pp. 992). FL, Orlando: ELSEVIER. DOI WoS10 |
| 2023 | Branford, S., Wadham, C., Shanmuganathan, N., Fernandes, A., Shahrin, N. H., Feng, J., . . . Hughes, T. P. (2023). Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML. In BLOOD Vol. 142 (pp. 5 pages). CA, San Diego: ELSEVIER. DOI WoS5 |
| 2022 | Poudel, G., Yeung, D. T., White, D. L., Hughes, T., & Pagani, I. S. (2022). <i>PTPN11</i> Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph plus ALL Cells, but Are Sensitive to the Combination. In BLOOD Vol. 140 (pp. 3128-3129). LA, New Orleans: AMER SOC HEMATOLOGY. DOI |
| 2022 | Branford, S., Shanmuganathan, N., Wadham, C., Shahrin, N. H., Fernandes, A., Feng, J., . . . Hughes, T. (2022). Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML. In BLOOD Vol. 140 (pp. 3916-3917). LA, New Orleans: ELSEVIER. DOI WoS1 |
| 2018 | Leow, B. C., Eadie, L., Pagani, I. S., Yeung, D. T., Hughes, T. P., & White, D. L. (2018). Clonal Selection Determines Resultant Dominance of Tyrosine Kinase Inhibitor-Resistant Cells in Chronic Myeloid Leukaemia. In HemaSphere Vol. 2 (pp. 503). Stockholm, Sweden: Lippincott, Williams & Wilkins. DOI |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A. K., Filshie, R. J., . . . Hughes, T. P. (2017). Long-term Follow-up of the ALLG CML8 TWISTER Study of Treatment-free Remission (TFR) in Patients With Chronic Myeloid Leukemia (CML).. In Blood Vol. 130 (pp. 1597). Atlanta: American Society of Hematology. |
| 2017 | Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . . . Ross, D. (2017). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. In Haematologica. Madrid: Ferrata Storti Foundation. |
| 2016 | Pagani, I. S., Kok, C. H., Saunders, V., Goyne, J., McLean, J., VanderHoek, M., . . . Ross, D. M. (2016). The genomic landscape of mitochondrial DNA mutations in chronic myeloid leukaemia.. In European Journal of Human Genetics. Barcelona: Natue Publishing Group. |
| 2016 | Pagani, I. S., Kok, C. H., Wang, J., Saunders, V., Goyne, J., McLean, J., . . . Ross, D. M. (2016). MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION. |
| 2014 | Pagani, I. S., Pirrone, C., & Amelotti, E. (2014). TAp73α regulates Otx1 expression during breast cancer stem cells differentiation and in response to cisplatin treatment.. In European Journal of Human Genetics. Milan: Nature Publishing Group. |
| 2014 | Pirrone, C., & Pagani, I. S. (2014). New molecular technique to monitor minimal residual diseased in CML. In European Journal of Human Genetics. Milan: Nature Publishing Group. |
| 2014 | Pagani, I. S., Spinelli, O., Pirrone, C., Amelotti, E., Lilliu, S., Intermesoli, T., . . . Porta, G. (2014). GENOMIC QUANTITATIVE REAL-TIME PCR ASSAY PROVES RESIDUAL DISEASE POSITIVITY IN MORE THAN 30% SAMPLES WITH NEGATIVE MRNA-BASED QRT-PCR RESULTS IN CHRONIC MYELOID LEUKEMIA. In BONE MARROW TRANSPLANTATION Vol. 49 (pp. S442-S443). Milan, ITALY: NATURE PUBLISHING GROUP. |
| 2013 | Pagani, I. S., Spinelli, O., Pirrone, C., Pigni, D., Lupoli, S., D'Avila, F., . . . Porta, G. (2013). Quantitative DNA Real-Time PCR Compared To mRNA and Cytogenetic Assays To Monitor Minimal Residual Disease In Chronic Myeloid Leukemia. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI |
| 2013 | Azzolini, C., & Pagani, I. S. (2013). Expression Of VEGF-A Gene In Normal Retina And In PVR Retina. In Investigative Ophthalmology & Visual Science. Seattle: Association for Research in Vision and Ophthalmology. |
| 2012 | Azzolini, C., & Pagani, I. S. (2012). Otx2 And VegfA Expression And P53-Otx1 Differentiation Pathway In Proliferative Vitreoretinopathy. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology. |
| 2011 | Pagani, I. S., Spinelli, O., Bussini, A., Intermesoli, T., Pasquali, F., Lo Curto, F., . . . Porta, G. (2011). Chronic Myeloid Leukemia: Molecular Monitoring of Residual Disease by Genomic DNA Compared to Conventional mRNA Analysis in Follow-Ups up to 8 Years. In BLOOD Vol. 118 (pp. 733). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Pagani, I. S., Terrinoni, A., Zucchi, I., Chiaravalli, A. M., Serra, V., Rovera, F., . . . Alberti, A. (2011). p53 family members regulate the Otx1 gene expression in differentiation of breast cancer stem cells and in mammary gland development. In FEBS JOURNAL Vol. 278 (pp. 471-472). Torino, ITALY: WILEY-BLACKWELL. |
| 2011 | Azzolini, C., Donati, C., Borroni, D., Moriondo, A., & Pagani, I. S. (2011). Evaluation of the p53-Otx1 pathway in the retina.. In Investigative Ophthalmology & Visual Science. Fort Lauderdale, Florida, US: Association for Research in Vision and Ophthalmology. |
| Year | Citation |
|---|---|
| 2024 | Pagani, I. S., Krishnan, V., Ouyang, J., Kok, C. H., Chen, B., Page, E. C., . . . Ross, D. M. (2024). Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity. Poster session presented at the meeting of BLOOD. ELSEVIER. DOI |
| 2020 | Poudel, G., Yeung, D., White, D., Hughes, T., & Pagani, I. (2020). Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poster session presented at the meeting of The 59th ASMR National Scientific Conference. |
| 2018 | Pagani, I. S., Kok, C., Saunders, V., Schwarer, A., Hughes, T. P., White, D. L., & Ross, D. M. (2018). Association of mitochondrial DNA (mtDNA) mutations at diagnosis with treatment response in chronic myeloid leukaemia (CML) patients. Poster session presented at the meeting of NDLR. |
| 2017 | Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . Hughes, T. P. (2017). Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Poster session presented at the meeting of 59th ASH Annual Meeting & Exposition. |
| Year | Citation |
|---|---|
| 2025 | Pagani, I. S., Krishnan, V., John, O. F., Kok, C. H., Chen, B., Lee, K. L., . . . Ross, D. M. (2025). Mitochondrial DNA Mutations Determine Favourable Molecular Responses to Targeted Kinase Inhibitor Therapy and Impair Oxidative Phosphorylation. DOI |
2021: Pagani IS, Hughes TP. Leukaemia Foundation $102,050, first six-month Strategic Ecosystem Research Partnership grant. "A new precision medicine approach for achieving treatment-free remission in chronic myeloid leukaemia". Award date: 09/2021. 01/09/2021→ 28/02/2022.
2020: Beat Cancer Project COVID-19 Hardship Grant - $8,000-, and 3-months extension of the Beat Cancer project Mid-career fellowship.
2019: Beat Cancer Research Mid-Career Fellowship- $600,000, Granted by Cancer Council South Australia's Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health and Wellbeing.”'
2019: Pagani IS, Rao SR, Trim P, Ryan F, Lynn D, Ross DM, Thomas D. SAHMRI Mid-Career Seed Funding Grant ($30,000). "Identifying and exploiting metabolic dependencies for improved therapeutic outcomes in chronic myeloid leukaemia patients". Award date: 01/01/2020→ 31/12/2020.
2019: Pagani IS, Ross DM, Hughes TP, Yong A, Branford S, Kok CH, Shanmuganathan N, Gray T, Irani Y. Winner of the First European School of Haematology (ESH) International John Goldman Research Award ($130,000). "Use of machine learning to integrate clinical data and biomarkers to optimize prediction of TFR". Award date: 22/05/19; 1/10/19 → 30/09/21.
2015: David Ross, Ilaria Pagani and Deb White. Contributing Haematologists’ Committee ($200,000). - "Do mitochondrial mutations in chronic myeloid leukaemia identify a pre-leukaemic clone".
2020: I joined Romana Panagopolous delivering workshops in Professor Tania Crotti, 3rd yr. Bch Health and Med Science topic Investigative Cell Biology.
2010: Biochemistry III tutorial, Adelaide University, Australia.
2019: Biochemistry III tutorial, Adelaide University, Australia.
2018: Biochemistry III tutorial, University of Adelaide, Australia.
2016: Biochemistry III tutorial, Adelaide University, Australia.
2007-2013: Lectures and Tutorial of Laboratory Techniques and Genetics to Medical Students, Insubria University, Varese, Italy.
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2024 | Principal Supervisor | Modelling resistant mutations in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Zuhal Naderi |
| 2024 | Principal Supervisor | Modelling resistant mutations in Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Zuhal Naderi |
| 2023 | Principal Supervisor | Investigating the role of lipid metabolism in chronic myeloid leukaemia | Doctor of Philosophy | Doctorate | Full Time | Miss Molly Gladys Tolland |
| 2023 | Principal Supervisor | Investigating the role of lipid metabolism in chronic myeloid leukaemia | Doctor of Philosophy | Doctorate | Full Time | Ms Molly Tolland |
| 2021 | Co-Supervisor | Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Part Time | Miss Adelina Catherina B. Fernandes |
| 2021 | Co-Supervisor | Genomic Mechanisms Influencing Outcome In Chronic Myeloid Leukaemia | Doctor of Philosophy | Doctorate | Part Time | Miss Adelina Catherina B. Fernandes |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2019 - 2023 | Co-Supervisor | Unravelling Resistance Mechanisms in Philadelphia Positive Leukemias: Targeted Treatment Strategies to Overcome Resistance | Doctor of Philosophy | Doctorate | Full Time | Mr Govinda Poudel |
| Date | Role | Research Topic | Location | Program | Supervision Type | Student Load | Student Name |
|---|---|---|---|---|---|---|---|
| 2022 - ongoing | Principal Supervisor | Exploiting lipid metabolism on chronic myeloid leuakemia | SAHMRI | Masters of Philosophy | Other | Full Time | Molly Tolland |
| 2019 - 2019 | Principal Supervisor | Measurement of mitochondrial respiration via seahorse experiments using frozen MNCs from CML patients | SAHMRI | SAHMRI Summer Research Scholarship | Other | Full Time | Lian Tran |
| 2019 - 2019 | Principal Supervisor | DNA QPCR assay for the monitoring of minimal residual disease in CML patients | SAHMRI | SAHMRI Summer Research Scholarship | Other | Full Time | Tarin Ritchie |
| 2018 - ongoing | Principal Supervisor | Mitochondrial DNA mutations in CML | The University of Adelaide | Placement | Other | Part Time | Samuel Cannata, Rico Acuna |
| 2018 - ongoing | Co-Supervisor | Mitochondrial DNA copy Numbers in MPN | UniSA | Placement | Other | Part Time | Lian Thuy |
| 2017 - ongoing | Principal Supervisor | Monitoring BCR-ABL content in 2 Chronic Myeloid Leukaemia (CML) Patients Involved in a Trial of Treatment Free Remission (TFR) | The University of Adelaide | Placement | Other | Part Time | Caitlin Skinner |
| 2014 - ongoing | Co-Supervisor | Next generation Sequencing in CML | Insubria University | - | Postdoctorate | - | Pirrone Cristina |
| 2011 - ongoing | Principal Supervisor | Monitoring of minimal residual disease in CML by gDNA QPCR | Insubria University, Varese, Italy | - | Master | Full Time | Giorgia Aimoni |
| 2011 - ongoing | Principal Supervisor | Monitoring of Minimal Residual Disease in CMl | Insubria University | - | Master | - | Pirrone Cristina |
| 2011 - 2013 | Principal Supervisor | Next-Generation Sequencing as a new approach to monitor minimal residual disease in CML | Insubria University | - | Doctorate | Full Time | Pirrone Cristina |
| 2011 - ongoing | Co-Supervisor | p53-Otx1 in retina | Faculty of Medicine, Insubria University, | - | Master | - | Borroni Davide |
| 2009 - 2011 | Principal Supervisor | p53 and Otx1 in Glioblastoma and Breast Cancer | Faculty of Medicine, Insubria University | Placement | Other | - | Annalisa Paolino, Eleonora Scotti, Martina Baiardo |
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 2022 - 2026 | Treasurer | Committee of Italians Abroad (Com.It.Es) - South Australia | Italian Government | Australia |
| 2020 - ongoing | Board Member | Radio Italiana 531 Youth | Radio Italiana 531 | Australia |
| 2020 - ongoing | Founder | Association of Italian Researchers in Australasia - ARIA | Association not for profit | Australia |
| 2020 - ongoing | President | Association for Italian Researchers in Australasia – South Australia (ARIA). | Association for Italian Researchers in Australasia – South Australia (ARIA). | Australia |
| 2019 - ongoing | Board Member | Myeloid Leukaemia Consumer Advisory Gro | SAHMRI | Australia |
| Date | Event Name | Event Type | Institution | Country |
|---|---|---|---|---|
| 2021 - ongoing | 50th Anniversary of the Italian Republic | Receptions | Government of South Australia | - |
Connect With Me
External Profiles
